2993-07-9

Usage

Uses

Used in Pharmaceutical Industry:
3,4,5,6-Tetrafluorobenzene-1,2-diaMine is used as a chemical intermediate for the synthesis of various halogenated compounds. These compounds have been found to induce Hep2 cell apoptosis, which is a significant process in the development of cancer treatments. By targeting cancer cells and promoting apoptosis, these halogenated compounds can potentially contribute to the treatment of various types of cancer.
Used in Chemical Synthesis:
3,4,5,6-Tetrafluorobenzene-1,2-diaMine can also be utilized as a building block in the synthesis of more complex organic molecules, particularly those with fluorinated structures. The presence of the amine functional groups allows for further chemical reactions, such as alkylation, acylation, or formation of imines, to create a wide range of compounds with diverse applications in various industries.

Upstream product

• 6157-98-8 2,3,4,5-tetrafluoro-6-nitroaniline 
• 344-07-0 1-chloro-2,3,4,5,6-pentafluorobenzene 
• 123394-96-7 1-pentafluorophenyl-3-trimethylsilyl-1,3-diaza-2-thiaallene 
• 771-60-8 2,3,4,5,6-pentafluoroaniline 
• 7732-18-5 water 
• 2247-97-4 3-N₂H₃-C₆F₄NH₂ 
• 1801-15-6 2-(2,3,4,5,6-pentafluoro-anilino)-ethanol 
• 30807-79-5 C₆HBCl₂F₅N 
• 16582-88-0 N-(2,3,4,5-tetrafluorophenyl)acetamide 
• 880-78-4 pentafluoronitrobenzen 
• 75207-77-1 4.5.6.7-tetrafluorobenzo-2.1.3-thiadiazole 

Downstream Products

• 4920-46-1 4,5,6,7-tetrafluorobenzimidazole 
• 26888-72-2 4,5,6,7-tetrafluorobenzotriazole 
• 26888-63-1 5,6,7,8-tetrafluoro-2,3-diphenylquinoxaline 
• 39063-17-7 N,N-(perfluoro-1,2-phenylene)bis(2,2,2-trifluoroethanamide) 
• 4920-47-2 4,5,6,7-tetrafluoro-N-methylbenzimidazole 
• 1240404-70-9 N,N'-disulfinyl-3,4,5,6-tetrafluoro-1,2-diaminobenzene 
• 1258949-68-6 N,N'-bis-pentafluorophenyl-3,4,5,6-tetrafluorophenylene-1,2-diamine 
• 554-68-7 triethylamine hydrochloride 
• 81430-68-4 1-ethyl-2-methyl-3,3,3-trifluoropropyl-4,5,6,7-tetrafluorobenzimidazolium p-toluenesulfonate 
• 81430-66-2 1,3-diethyl-2-methyl-4,5,6,7-tetrafluorobenzimidazolium p-toluenesulfonate 
• 81430-75-3 2-methyl-4,5,6,7-tetrafluorobenzimidazole 
• 2355-43-3 4,5,6,7-Tetrafluor-2-trifluormethyl-benzimidazol 
• 81430-63-9 3,4,5,6-tetrafluoro-N,N'-bis(diacetyl)-o-phenylendiamine 

Relevant academic research and scientific papers

2-(4,5,6,7-Tetrafluorobenzimidazol-2-yl)-4,4,5,5-tetramethyl-4,5-dihydro-1- H-imidazole-3-oxide-1-oxyl, a hydrogen-bonded organic quasi-1D ferromagnet

The title radical (F4BImNN) is a stable nitronylnitroxide that forms hydrogen-bonded NH?ON chains in the solid state. The chains assemble the F4BImNN molecules to form stacked contacts between the radical groups, in a geometry that is expected to exhibit

CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF

Briefly described, embodiments of this disclosure include charge-transport materials, methods of forming charge-transport materials, and methods of using the charge-transport materials.

Catalytic and noncatalytic ammonolysis of chloropentafluorobenzene

Ammonolysis of chloropentafluorobenzene both in the presence and in the absence of copper(I) salt results mainly in replacement of the para-and ortho-fluorine atoms with respect to chlorine rather than replacement of the chlorine atom. Ammonolysis of 4-chloro-2,3,5,6-tetrafluoroaniline and 2-chloro-3,4,5,6-tetrafluoroaniline in the absence of copper(I) salt yields exclusively the corresponding fluorine substitution products, whereas in the presence of copper(I) salt the chlorine atom is replaced. Successive ammonolysis of chloropentafluorobenzene in the presence of copper catalyst along these two paths was put into the basis of a new method for preparation of 2,3,5,6-tetrafluoro-1,4-phenylenediamine. * This study was financially supported by the Russian Foundation for Basic Research (project no. 99-03-33111), by the Ministry of Science and Technology of the Russian Federation (project no 9.3.01), and by the Ministry of Education of the Russian Federation (project no. 015.05.01.13).

Polyhalogenonitrobenzenes and derived compounds: Part 5. Improved preparations of 1,2,3,4-tetrafluoro-5,6-dinitrobenzene and 3,4,5,6-tetrafluoro-1,2-phenylenediamine, and the use of the latter for the synthesis of tetrafluorobenzheterocycles

The preparation of 2,3,4,5-tetrafluoro-6-nitroaniline (3) by amination of pentafluoronitrobenzene has been speeded up, scaled up and the yield increased by controlling the reaction by TLC monitoring and using 'dry column' chromatography. Compound (3) was readily converted to 1,2,3,4-tetrafluoro-5,6-dinitrobenzene (2) by peroxytrifluoroacetic acid and to 3,4,5,6-tetrafluoro-1,2-phenylenediamine (1) by SnCl2/HCl, Compound (1) was shown to be a versatile intermediate for the synthesis of tetrafluoro-benzimidazoles, -triazoles and -quinoxalines. The fungicidal activity of the latter are reported here.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.

CYCLIC ARYLENEAZACHALCOGENENES PART III. SYNTHESIS OF POLYFLUORINATED 2,1,3-BENZOTHIA(SELENA)DIAZOLES

1-(4-X-Tetrafluorophenyl)-3-trimethylsilyl-1,3-diaza-2-thiaallenes (X= H, CH3, Br, F, CF3) treated with CsF in acetonitrile or THF cyclized to 6-X-4,5,7-trifluoro-2,1,3-benzothiadiazoles whose reduction led to the corresponding 1,2-diaminobenzenes.Cyclization of the latter with SeCl4 gave 6-X-4,5,7-trifluoro-2,1,3-benzoselenadiazoles.